<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carnitine supplements (Levocarnitine): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carnitine supplements (Levocarnitine): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carnitine supplements (Levocarnitine): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10799" href="/d/html/10799.html" rel="external">see "Carnitine supplements (Levocarnitine): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13119" href="/d/html/13119.html" rel="external">see "Carnitine supplements (Levocarnitine): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F187916"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Carnitor;</li>
<li>Carnitor SF;</li>
<li>G-levOCARNitine S/F [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867357"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Carnitor;</li>
<li>ODAN Levocarnitine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F187947"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Dietary Supplement</li></ul></div>
<div class="block doa drugH1Div" id="F187919"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="617a5bde-4a3c-448f-8c41-b907f8c62b8d">Carnitine deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Carnitine deficiency: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Primary or secondary: Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral solution:</b> Initial: 1,000 mg/day in divided doses (every 3 to 4 hours throughout the day); titrate slowly as needed to 1,000 to 3,000 mg/day in divided doses based on tolerance and therapeutic response; higher doses may be needed in some patients (administer only with caution).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Tablet:</b> 990 mg 2 to 3 times a day, depending on clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Secondary: IV:</b> 50 mg/kg/day in divided doses (every 3 to 6 hours); subsequent doses in the range of 50 mg/kg/day or higher if clinically indicated (maximum reported dose: 300 mg/kg/day). In patients with severe metabolic crisis, a 50 mg/kg loading dose followed by an additional 50 mg/kg in divided doses over the next 24 hours may be required.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f927bd6-d5cb-497b-81c7-194a125c1b95">Carnitine deficiency in patients with ESRD requiring dialysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Carnitine deficiency in patients with ESRD requiring dialysis:</b>
<b>IV:</b> 10 to 20 mg/kg (dry body weight) after each dialysis session; guide dosage adjustments by trough (predialysis) levocarnitine concentrations. Evaluate clinical response at 3-month intervals and titrate to the lowest effective dose; therapy should be discontinued if no improvement is seen after 9 to 12 months of therapy (Eknoyan 2003). <b>Note:</b> Current guidelines do not support the routine use of levocarnitine in dialysis patients (K/DOQI guidelines 2000); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan 2003).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81863c66-ac4f-45ff-b638-ded564c6efe2">Dietary supplement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplement (OTC use): Oral:</b> Refer to individual product labeling.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="051ebf11-ccf1-4983-9847-35e8d390187a">Valproic acid toxicity, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Valproic acid toxicity, acute (off-label use):</b>
<b>IV: </b>Initial: 100 mg/kg as an IV bolus followed by 50 mg/kg (maximum: 3,000 mg) as an IV bolus or intermittent infusion (over 15 to 30 minutes) every 8 hours; continue until ammonia levels are decreasing and clinical improvement is evident; patients may require several days of therapy (Perrott 2010). Some experts recommend a higher maximum loading dose (eg, 100 mg/kg [maximum: 6,000 mg]) and smaller, more frequent maintenance doses (eg, 15 mg/kg every 4 to 6 hours) in symptomatic patients (EASL 2019; Howland 2019; Russell 2007).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991442"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;">Oral: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, safety and efficacy of oral carnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high oral doses to patients with severely compromised renal function or ESRD patients on dialysis may result in accumulation of potentially toxic metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;">IV:  There are no dosage adjustments provided in the manufacturer’s labeling; dosage adjustments should be determined by levocarnitine levels and clinical response. <b>Note:</b> Current guidelines do not support the routine use of levocarnitine in dialysis patients (K/DOQI guidelines 2000); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan 2003).</p></div>
<div class="block doha drugH1Div" id="F50988744"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Oral, IV: There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F187920"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F187936"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13119" href="/d/html/13119.html" rel="external">see "Carnitine supplements (Levocarnitine): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c3aae88-a83b-439a-89cd-d67ee5d155f1">Carnitine deficiency, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Carnitine deficiency, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Variability in gene-specific mutations and clinical presentations exist; dosage should be individualized based upon patient response and serum carnitine concentrations with consultation with a metabolic specialist.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Primary deficiency:</i> Infants, Children, and Adolescents: Oral: Initial: 50 to 100 mg/kg/<b>day</b> in divided doses; reported frequency varies from 2 to 4 times daily up to every 3 to 4 hours; may titrate slowly as needed based on serum carnitine concentrations; reported range: 100 to 400 mg/kg/<b>day</b>; maximum daily dose: 3,000 mg/<b>day</b> (Almannai 2019; BIMDG 2016a; BIMDG 2020; Longo 2006; Longo 2016; Magoulas 2012; Stanley 2020; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Secondary deficiency:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">Oral: Initial: 50 to 100 mg/kg/<b>day</b> in divided doses; reported frequency varies from 2 to 4 times daily up to every 3 to 4 hours; may titrate slowly as needed based on patient response; usual dose: 100 to 200 mg/kg/<b>day</b>; some patients may require higher doses (eg, 300 mg/kg/<b>day</b>); maximum daily dose: 3,000 mg/<b>day </b>(BIMDG 2016b; BIMDG 2020; Boy 2017; Shchelochkov 2020; Sutton 2012; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:10em;">IV: 50 to 100 mg/kg as a single dose; titrate based on patient response. In patients with severe metabolic crisis, administer a loading dose based on patient's usual therapy, followed by an equivalent dose given over the next 24 hours as a continuous infusion or divided every 3 to 6 hours; some conditions may require higher daily doses (eg, 300 mg/kg/<b>day</b>) (BIMDG 2016b; BIMDG 2020; Boy 2017; Shchelochkov 2020; Sutton 2012; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e619f2b-e0c1-4c60-844a-27cfaeef1c21">Carnitine deficiency in patients with end-stage renal disease requiring dialysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Carnitine deficiency in patients with end-stage renal disease (ESRD) requiring dialysis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although described in manufacturer labeling, current guidelines do not support the use of levocarnitine in patients on dialysis (KDOQI 2009; KDIGO 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 10 to 20 mg/kg dry body weight after each dialysis session; titrate dose based on serum concentrations; lower doses may be sufficient (manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="47bd9ca6-709c-4dcb-a0e4-d67f5e44f74f">Cyclic vomiting syndrome, supplemental/adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, supplemental/adjunctive therapy:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: Initial: 50 to 100 mg/kg/day in divided doses 2 or 3 times daily; usual maximum dose: 1,000 mg/dose twice daily; higher doses (eg, up to a daily dose of 4,000 mg/<b>day</b>) have been used if needed based on laboratory testing of blood carnitine levels; however, this should be done with caution and careful monitoring of adverse events (eg, diarrhea) (Boles 2011; Kovacic 2018; Li 2018; Maqbool 2020; NASPGHAN [Li 2008]; Raucci 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="051ebf11-ccf1-4983-9847-35e8d390187a">Valproic acid toxicity, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Valproic acid toxicity, acute:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Dosing based on level of hepatic involvement and should be adjusted based on clinical response or serum level of valproic acid:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>No hepatotoxicity:</i> IV: 100 mg/kg/<b>day</b> divided every 6 hours until serum ammonia and valproic acid concentrations begin to decrease and clinical improvement is evident; maximum daily dose: 3,000 mg/<b>day</b> (Russell 2007).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Symptomatic hyperammonemia or hepatotoxicity:</i> Reported dosing regimens variable: IV: Loading dose: 100 mg/kg; maximum loading dose: 6 <b>g</b>; followed by 15 mg/kg/dose every 4 to 6 hours; continue treatment until serum ammonia concentrations begin to decrease and clinical improvement is evident; patients may require several days of therapy. Doses of 50 mg/kg/dose (up to 3,000 mg/dose) every 8 hours have also been described (EASL 2019; Howland 2019; Perrott 2010; Russell 2007).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51117866"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: There are no dosage adjustments provided in the manufacturer's labeling; safety and efficacy of oral carnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high oral doses to patients with severely compromised renal function or with end-stage renal disease on dialysis may result in accumulation of potentially toxic metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: There are no dosage adjustments provided in the manufacturer's labeling; dosage adjustments should be determined based on levocarnitine levels and clinical response.</p></div>
<div class="block dohp drugH1Div" id="F51117867"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral, IV: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F187888"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Adverse reactions include intravenous use in hemodialysis patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, chest pain, ECG abnormality, hypertension, palpitations, peripheral edema, tachycardia, vascular disease</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Body odor, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia, parathyroid disorder, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, diarrhea, dysgeusia, gastritis, melena, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, hypersensitivity reaction (including anaphylaxis, bronchospasm, and laryngeal edema)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, depression, dizziness, headache, myasthenia (uremic patients), paresthesia, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia, eye disease</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, cough, rhinitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F14725394"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Hypersensitivity to levocarnitine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F187885"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: GI reactions may result from too rapid consumption of oral carnitine; consume oral solution slowly and space doses evenly throughout the day to maximize tolerance.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious hypersensitivity reactions have been reported after oral (eg, rash, urticaria, facial edema) and intravenous (eg, anaphylaxis, laryngeal edema, and bronchospasm) administration. Reactions from IV use have typically occurred in patients with end stage renal disease on dialysis and may occur within minutes after use. Discontinue immediately and institute appropriate medical therapy if an acute reaction occurs; consider risks and benefits of reinitiating therapy, and monitor patient for recurrence of severe hypersensitivity reaction if therapy is reinstated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Carnitine deficiency: Risk factors include: Age (infants and young children are deficient in the enzyme that activates carnitine), chronic valproic acid administration, concomitant neurologic disorders, congenital metabolic disorders, hepatic cirrhosis, renal failure, critical care patients (burns, sepsis, trauma, organ failure), use of multiple antiseizure drugs and other drugs (chemotherapy agents, antinucleoside analogues) (Katiyar 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Safety and efficacy of oral carnitine have not been evaluated in patients with renal insufficiency. Chronic administration of high oral doses to patients with severely compromised renal function or ESRD patients on dialysis may result in accumulation of potentially toxic metabolites.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with seizure disorders or in those at risk of seizures; both new-onset seizure activity as well as an increased frequency and/or severity of seizures has been observed.</p></div>
<div class="block foc drugH1Div" id="F187896"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carnitor: 200 mg/mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carnitor: 1 g/10 mL (118 mL) [contains methylparaben, propylparaben; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carnitor SF: 1 g/10 mL (118 mL) [sugar free; contains methylparaben, propylparaben, saccharin sodium; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">G-levOCARNitine S/F: 1 g/10 mL (474 mL) [sugar free; contains methylparaben, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/10 mL (5 mL, 10 mL, 118 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carnitor: 330 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 330 mg</p></div>
<div class="block geq drugH1Div" id="F187881"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F187903"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Acticarnitine SF Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Carnitor Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/mL (per mL): $9.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Carnitor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $0.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Carnitor SF Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $0.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (levOCARNitine (Dietary) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $0.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (levOCARNitine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/mL (per mL): $8.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (levOCARNitine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/10 mL (per mL): $0.39</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Carnitor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">330 mg (per each): $1.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (levOCARNitine (Dietary) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">330 mg (per each): $0.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (levOCARNitine L-Tartrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">330 mg (per each): $0.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (levOCARNitine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">330 mg (per each): $1.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867358"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carnitor: 200 mg/mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carnitor: 10% (118 mL) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (118 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carnitor: 330 mg</p></div>
<div class="block adm drugH1Div" id="F187899"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral solution:</b> Solution is for oral use only (not for parenteral use); may be consumed alone or dissolved in either a drink or liquid food, and should be consumed slowly. Space doses every 3 to 4 hours evenly throughout the day, preferably during or following meals, to maximize tolerance.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Carnitine deficiency: Administer as a bolus dose over 2 to 3 minutes or by infusion. Doses should be administered every 3 to 4 hours, but never less than every 6 hours (eg, 4 doses/day).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis patients: Administer as a bolus dose over 2 to 3 minutes into the venous return line after each dialysis session.</p></div>
<div class="block admp drugH1Div" id="F52613143"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Oral solution: Administer undiluted or diluted in either beverages or liquid food; consume slowly; doses should be spaced evenly throughout the day, preferably during or following meals to improve tolerance.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carnitine deficiency:</i> May be administered undiluted (200 mg/mL) as IV push over 2 to 3 minutes or further diluted and administered as intermittent IV infusion over 30 minutes or as continuous infusion (BIMDG 2016a).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>End-stage renal disease on hemodialysis:</i> May be administered undiluted (200 mg/mL) as IV push over 2 to 3 minutes into the venous return line.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Valproic acid toxicity:</i> May be administered undiluted (200 mg/mL) as IV push over 2 to 3 minutes or further diluted and administered as IV infusion over 10 to 30 minutes (Howland 2019; Perrott 2010; Russell 2007).</p></div>
<div class="block use drugH1Div" id="F187898"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Carnitine deficiency in patients with end-stage renal disease requiring hemodialysis (injection only):</b> Prevention and treatment of carnitine deficiency in patients with end-stage renal disease (ESRD) who are undergoing dialysis.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Dietary supplement (OTC only):</b> As a levocarnitine dietary supplement.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Primary systemic carnitine deficiency (oral [Rx] only):</b> Treatment of primary systemic carnitine deficiency.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Secondary carnitine deficiency (oral [Rx] and injection):</b> Acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.</p></div>
<div class="block off-label drugH1Div" id="F25473348"><span class="drugH1">Use: Off-Label: Adult</span><p>Elevated ammonia levels, coma, and/or hepatic dysfunction due to valproic acid overdose/toxicity</p></div>
<div class="block mst drugH1Div" id="F187954"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">LevOCARNitine may be confused with levETIRAcetam, levocabastine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299590"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221274"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): LevOCARNitine may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F187904"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Teratogenic effects were not observed in animal studies. Carnitine is a naturally occurring substance in mammalian metabolism.</p></div>
<div class="block brc drugH1Div" id="F187905"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">In breast-feeding women, use must be weighed against the potential exposure of the infant to increased carnitine intake. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F187894"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Carnitine concentrations (initially, weekly, and monthly for IV therapy)</p>
<p style="text-indent:-2em;margin-left:4em;">Metabolic disorders: Monitor blood chemistry, vital signs, and plasma carnitine levels (maintain between 35 to 60 μmol/L). In ESRD patients on dialysis: National Kidney Foundation guidelines recommend basing treatment on clinical signs and symptoms; evaluate response at 3-month intervals and discontinue if no clinical improvement noted within 9 to 12 months (Eknoyan 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">Valproic acid toxicity: Evaluate valproic acid concentrations (every 4 to 6 hours until a downward trend is observed), electrolytes, blood gases, mental status, hepatic function, serum ammonia concentration, serum lactate, and platelets.</p></div>
<div class="block rer drugH1Div" id="F187897"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Normal carnitine levels are 40 to 50 micromole/L; levels should be maintained on therapy between 35 to 60 micromole/L</p></div>
<div class="block pha drugH1Div" id="F187884"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Carnitine is a naturally occurring metabolic compound which functions as a carrier molecule for long-chain fatty acids within the mitochondria, facilitating energy production. Carnitine deficiency is associated with accumulation of excess acyl CoA esters and disruption of intermediary metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">In patients with valproic acid toxicity, the administration of exogenous carnitine shifts the metabolism of valproic acid toward beta-oxidation and away from omega-oxidation and potentially hepatotoxic metabolite production (Baddour 2018; Eyer 2005).</p></div>
<div class="block phk drugH1Div" id="F187901"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: None</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; Major metabolites: Trimethylamine (TMA) and trimethylamine N-oxide (TMAO)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral solution: 15.9% ± 4.9%; Tablet: 15.1% ± 5.3%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 17.4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Oral: 3.3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (76%, 4% to 8% as unchanged drug); feces (&lt;1%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F187906"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">L carnitine | L Carnitine | L-carnitine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Albicar | Carnitina | L Carnitina | L carnitina | Tonekin plus</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Biocarn | L-carnitin | Nefrocarnit</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">L-carnithine | L-carnitine | Thermo blast</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Carnitab | Carniten | Cartine | Envitor | Lenit | Levocar | Ocarnix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">L carnitine | L-carnitine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">L carnitina | Maxx carnitine</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Carnitene</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Carnitine | Lei ka</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Carnisin | Carnitene | Carnitinova | Carnitor | Lecarnin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Carnitene | L carnitin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Allgamed | Biocarn | Cadion L Carnitin | Carnitin | Carnityl | Carnivita | CC Vital L Carnitin | Drofa l-carnitin | Echt vital L carnitin | Greenleaves vitamins acetyl l carnitin | L carnitin | L Carnitin | L carnitin 500 | L carnitine | L Carnitine | L-carnitin | Makomed L Carnitin | Manako L-Carnitin | Megamax L Carnitin | Nefrocarnit | Olebauer L Carnitine Fat Metabolism Support | Omnivit l Carnitin | Orthoextra carnitin | PhysiCal L-Carnitin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cardispan | Carnisin | Provicar</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Carnisin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Carnitene | Mr.max l-carnitine | Now L carnitine | Weight loss</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amricarnitine | Carnitene | Carnitine | Carnitol | Carnivita | Hydro bern | L-carnitine | L-carnttne | Levocarnine | Sunnycarnitine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Carnicor | Secabiol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Levocarnil</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Carnitor | Levocarnitine | Levocarnitine paediatric</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Frutenor | Inestom | Levalastine | Levosan | Superamin | Trian | Trinalin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Carnitene | Carnitor</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Carnitor</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">L-carnitine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Carnicare | Carnidin | Carniglo | Carnikid | Carnimed | Carnisure | Carnitor | Carnix | L-carpro | Lacarnit | Lencar | Levocarnil | Myocarnit | Nucarnit | Recarnit | Ree</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Branitil | Carnitene | Carnitina | Dromos | L-Carnitina | L-carnitina fonten | Lefcar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">L carnitine | L Carnitine | L-Carnitine | L-carnitine | Lynae l-carnitine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">L Cartin | Levocarnitine chloride | Levocarnitine ff | Rhythm</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Antifat | Carditone | Carnil | Cartin | Cartine l | D catin | Elcadol | Elgatin | Kaniel | Kareuel | L canin | L carina | L carnin | L carthin | L cartil | L catil | L liss | L queen | L tine | L top | L-carn | Lcaline | Lcanil | Lcarina | Lq | Myelcatin | Neucarotine | Slican</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">L Carnitine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">L Carnitine | L carnitine | L karnitin | L-carnitine | Supravit l carnitine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Carnitor | L carnitin | L carnitine | L-carnitine | L-Carnitine | Nefrocarnit</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acetil l carnitine | Bio-carnitin | L Carnitine | L-Carnitine | Mr.max l-carnitina</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cardispan | L-carnitina | Mince | Novacart | Provicar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Carnitor | Gnc l carnitine | L Carnitine | L carnitine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Carnitene | Levocarnitine eureco pharma | Levocarnitine Fisher | Nefrocarnit</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Carnicor | Carnitor | L-carnitin gph | Max carnitine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">L-carnitine | Solgar l carnitine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cardispan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cardimax | Carnicor | Legarde</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Carnitor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Carnitine | Carnitor | Carnitor SF | L carnitine | L-carnitine | Levocarnitine</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Carnitine | Elcar | Nephrocarnitis</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Natrol l carnitine | Spermotil</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">L carnitine | L-carnitine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Nefrocarnit</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Carnitene</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bio carnitine | L-carnitine | Vistra L Carnitine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Levocarnil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Carnitene | L-carnitine | Nefro Carnitin | Nutraxin L Carnitine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Carenephrin | Carnitene | Levocarnitin | Levolysis | Sinitine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Agvantar | Almiba | Cardonat l-carnitine | Carnivit | Steatel</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Carnitil | Carnitina | Elecar | L-carnitine</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Carnisin | Carnitene | Kativil | L carnitina | L-carnitina | Lecarnin | Lecart | Levocar | Lixi | Provicar | Rocarnin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Anbaluti</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Carnitine | Essentials l carnitine | Gold l carnitine | L carnitine | L Carnitine | L-carnitine</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Carnisure</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31500110">
<a name="31500110"></a>Almannai M, Alfadhel M, El-Hattab AW. Carnitine inborn errors of metabolism. <i>Molecules</i>. 2019;24(18):3251. doi:10.3390/molecules24183251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/31500110/pubmed" id="31500110" target="_blank">31500110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955549">
<a name="29955549"></a>Baddour E, Tewksbury A, Stauner N. Valproic acid-induced hyperammonemia: incidence, clinical significance, and treatment management. <i>Ment Health Clin</i>. 2018;8(2):73-77. doi:10.9740/mhc.2018.03.073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/29955549/pubmed" id="29955549" target="_blank">29955549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21846334">
<a name="21846334"></a>Boles RG. High degree of efficacy in the treatment of cyclic vomiting syndrome with combined co-enzyme Q10, L-carnitine and amitriptyline, a case series. <i>BMC Neurol</i>. 2011;11:102. doi:10.1186/1471-2377-11-102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/21846334/pubmed" id="21846334" target="_blank">21846334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27853989">
<a name="27853989"></a>Boy N, Mühlhausen C, Maier EM, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. <i>J Inherit Metab Dis</i>. 2017;40(1):75-101. doi:10.1007/s10545-016-9999-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/27853989/pubmed" id="27853989" target="_blank">27853989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BIMDG.1">
<a name="BIMDG.1"></a>British Inherited Metabolic Disease Group (BIMDG). Carnitine transporter deficiency (CTD) - acute decompensation. https://www.bimdg.org.uk/store/guidelines/ER-CTD-v4_376453_09092016.pdf. Updated September 2016a. Accessed July 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BIMDG.2">
<a name="BIMDG.2"></a>British Inherited Metabolic Disease Group (BIMDG). Glutaric aciduria type 1 - acute decompensation. https://www.bimdg.org.uk/store/guidelines/ER-GA1-v4_549337_05042017.pdf. Updated September 2016b. Accessed July 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BIMDG.3">
<a name="BIMDG.3"></a>British Inherited Metabolic Disease Group (BIMDG). National formulary for inherited metabolic diseases (IMDs) 2nd edition. https://www.bimdg.org.uk/store/docs/BIMDG_Metabolic_Formulary_Second_Edition_October2020FINAL_582433_25102020.pdf. Published October 2020. Accessed July 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burton.1">
<a name="Burton.1"></a>Burton BK. Inherited metabolic disorders. In: Boardman J, Groves A, Ramasethu J, eds. <i>Avery &amp; MacDonald's Neonatology</i>. 8th ed. LWW; 2021:chap. 55.</div>
</li>
<li>
<div class="reference">
                  Carnitor Oral Solution and Tablets (levocarnitine) [prescribing information]. Gaithersburg, MD: Leadiant Biosciences; June 2023.</div>
</li>
<li>
<div class="reference">
                  Carnitor Injection (levocarnitine) [prescribing information]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals Inc; April 2018.</div>
</li>
<li>
<div class="reference">
                  Carnitor SF (levocarnitine) [prescribing information]. Gaithersburg, MD: Leadiant Biosciences; February 2020.</div>
</li>
<li>
<div class="reference">
                  Carnitor (levocarnitine) [product monograph]. Scarborough, Ontario, Canada: Leadiant Biosciences Inc; April 2019.</div>
</li>
<li>
<div class="reference">
                  Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12666074">
<a name="12666074"></a>Eknoyan G, Latos DL, and Lindberg J, “Practice Recommendations for the Use of L-Carnitine in Dialysis-Related Carnitine Disorder. National Kidney Foundation Carnitine Consensus Conference,” <i>Am J Kidney Dis</i>, 2003, 41(4):868-76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/12666074/pubmed" id="12666074" target="_blank">12666074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30926241">
<a name="30926241"></a>European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. <i>J Hepatol</i>. 2019;70(6):1222-1261. doi:10.1016/j.jhep.2019.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/30926241/pubmed" id="30926241" target="_blank">30926241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16012283">
<a name="16012283"></a>Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz KD, Zilker T. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. <i>J Clin Psychopharmacol</i>. 2005;25(4):376-380. doi:10.1097/01.jcp.0000168485.76397.5c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/16012283/pubmed" id="16012283" target="_blank">16012283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.2019">
<a name="Howland.2019"></a>Howland MA. Antidotes in depth: L-carnitine. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18072149">
<a name="18072149"></a>Katiyar A and Aaron C, "Case Files of the Children's Hospital of Michigan Regional Poison Control Center: The Use of Carnitine for the Management of Acute Valproic Acid Toxicity," <i>J Med Toxicol</i>, 2007, 3(3):129-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/18072149/pubmed" id="18072149" target="_blank">18072149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19231749">
<a name="19231749"></a>KDOQI Work Group, "KDOQI Clinical Practice Guideline for Nutrition in Children With CKD: 2008 Update. Executive Summary," <i>Am J Kidney Dis</i>, 2009, 53(3 Suppl 2):S11-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/19231749/pubmed" id="19231749" target="_blank">19231749</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3:1-150.</div>
</li>
<li>
<div class="reference">
                  Kidney Disease Improving Global Outcomes (KDIGO) Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. <i>Kidney Intern Suppl</i>. 2012;2(4):288-335.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159612">
<a name="30159612"></a>Kovacic K, Sood M, Venkatesan T. Cyclic vomiting syndrome in children and adults: what is new in 2018? <i>Curr Gastroenterol Rep</i>. 2018;20(10):46. doi:10.1007/s11894-018-0654-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/30159612/pubmed" id="30159612" target="_blank">30159612</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  L-Carnitine [prescribing information]. Bohemia, NY: Nature's Bounty; received May 1, 2023.</div>
</li>
<li>
<div class="reference">
                  L-Carnitine [prescribing information]. Livonia, MI: Rugby Laboratories; July 2015.</div>
</li>
<li>
<div class="reference">
                  Levocarnitine [prescribing information]. Shirley, NY: American Regent Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19280426">
<a name="19280426"></a>Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. <i>Clin Toxicol</i>. 2009;47(2):101-111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/19280426/pubmed" id="19280426" target="_blank">19280426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728540">
<a name="18728540"></a>Li BU, Lefevre F, Chelimsky GG, et al, "North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Consensus Statement on the Diagnosis and Management of Cyclic Vomiting Syndrome," <i>J Pediatr Gastroenterol Nutr</i>, 2008, 47(3):379-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/18728540/pubmed" id="18728540" target="_blank">18728540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30076469">
<a name="30076469"></a>Li BUK. Managing cyclic vomiting syndrome in children: beyond the guidelines. <i>Eur J Pediatr</i>. 2018;177(10):1435-1442. doi:10.1007/s00431-018-3218-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/30076469/pubmed" id="30076469" target="_blank">30076469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27931018">
<a name="27931018"></a>Longo N. Primary carnitine deficiency and newborn screening for disorders of the carnitine cycle. <i>Ann Nutr Metab</i>. 2016;68(suppl 3):5-9. doi:10.1159/000448321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/27931018/pubmed" id="27931018" target="_blank">27931018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16602102">
<a name="16602102"></a>Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. <i>Am J Med Genet C Semin Med Genet</i>. 2006;142C(2):77-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/16602102/pubmed" id="16602102" target="_blank">16602102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22989098">
<a name="22989098"></a>Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. <i>Orphanet J Rare Dis</i>. 2012;7:68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/22989098/pubmed" id="22989098" target="_blank">22989098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Maqbool.1">
<a name="Maqbool.1"></a>Maqbool A, Li BUK, Liacouras CA. Cyclic vomiting syndrome. In: Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020: chap. 369.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22180549">
<a name="22180549"></a>Mock CM and Schwetschenau KH, "Levocarnitine for Valproic Acid-Induced Hyperammonemic Encephalopathy," <i>Am J Health Syst Pharm</i>, 2012, 69(1):35-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/22180549/pubmed" id="22180549" target="_blank">22180549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16678659">
<a name="16678659"></a>National Kidney Foundation, "KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease," <i>Am J Kidney Dis</i>, 2006, 47(5 Suppl 3):S11-145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/16678659/pubmed" id="16678659" target="_blank">16678659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10895784">
<a name="10895784"></a>National Kidney Foundation, “Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. K/DOQI,” <i>Am J Kidney Dis</i>, 2000, 35(6 Suppl 2):1-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/10895784/pubmed" id="10895784" target="_blank">10895784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20587742">
<a name="20587742"></a>Perrott J, Murphy NG, and Zed PJ, "L-Carnitine for Acute Valproic Acid Overdose: A Systematic Review of Published Cases," <i>Ann Pharmacother</i>, 2010, 44(7-8):1287-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/20587742/pubmed" id="20587742" target="_blank">20587742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rasania.1">
<a name="Rasania.1"></a>Rasania M, Ahmed NM, Prafulchandra BV, Jain S. Primary carnitine deficiency in a neonate. <i>Arch Med Health Sci</i>. 2021;9:314-316</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33224097">
<a name="33224097"></a>Raucci U, Borrelli O, Di Nardo G, et al. Cyclic vomiting syndrome in children. <i>Front Neurol</i>. 2020;11:583425. doi:10.3389/fneur.2020.583425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/33224097/pubmed" id="33224097" target="_blank">33224097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17496767">
<a name="17496767"></a>Russell S, "Carnitine as an Antidote for Acute Valproate Toxicity in Children," <i>Curr Opin Pediatr</i>, 2007, 19(2):206-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/17496767/pubmed" id="17496767" target="_blank">17496767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shchelochkov.1">
<a name="Shchelochkov.1"></a>Shchelochkov OA, Manoli I, Venditti CP. Isoleucine, leucine, valine, and related organic acidemias. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 103.6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stanley.1">
<a name="Stanley.1"></a>Stanley CA, Bennett MJ. Defects in metabolism of lipids. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 104.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21963082">
<a name="21963082"></a>Sutton VR, Chapman KA, Gropman AL, et al. Chronic management and health supervision of individuals with propionic acidemia. <i>Mol Genet Metab</i>. 2012;105(1):26-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/21963082/pubmed" id="21963082" target="_blank">21963082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22730042">
<a name="22730042"></a>Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. <i>Nutr Clin Pract</i>. 2012;27(4):440-491. doi:10.1177/0884533612446706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carnitine-supplements-levocarnitine-drug-information/abstract-text/22730042/pubmed" id="22730042" target="_blank">22730042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wojcik.1">
<a name="Wojcik.1"></a>Wojcik MH. Inborn errors of metabolism. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR, eds. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Lippincott Williams&amp; Wilkins; 2022:chap. 60.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10109 Version 283.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
